tbuckley/cabot-search huggingface dataset:
Brain-Type Natriuretic Peptide and Amino-Terminal Pro–Brain-Type Natriuretic Peptide Discharge Thresholds for Acute Decompensated Heart Failure
Authors: Casey N. McQuade, Marisa Mizus, Joyce W. Wald, Lee Goldberg, Mariell Jessup, Craig A. Umscheid
Journal: Annals of Internal Medicine (2016)

Background: Acute decompensated heart failure (ADHF) requiring hospitalization is associated with high postdischarge mortality and readmission rates. Purpose: To examine the association between achieving predischarge natriuretic peptide (NP) thresholds and mortality and readmission rates in adults hospitalized for ADHF. Data Sources: Multiple databases from 1947 to October 2016 (English-language studies only). Study Selection: Trials and observational studies that compared mortality and readmission outcomes between patients with ADHF achieving a specific predischarge NP goal and those not achieving the goal. Data Extraction: Two investigators independently extracted study characteristics and assessed study risk of bias. One author graded the overall strength of evidence, with review by a second author. Data Synthesis: One randomized trial, 3 quasi-experimental studies, and 40 observational studies were identified. The most commonly used thresholds were a brain-type NP (BNP) level of 250 pg/mL or less or an amino-terminal pro–brain-type NP (NT-proBNP) decrease of at least 30%. Achievement of absolute BNP thresholds reduced postdischarge all-cause mortality (7 of 8 studies) and the composite outcome of mortality and readmission (12 of 14 studies). Achievement of percentage-change BNP thresholds reduced the composite outcome (5 of 6 studies), and achievement of percentage-change NT-proBNP thresholds reduced all-cause and cardiovascular mortality (2 of 4 studies) and the composite outcome (9 of 9 studies). All findings were low-strength. The randomized trial, assessed as having high risk of bias, suggested that a predischarge decrease in NT-proBNP level was associated with lower risk for the composite outcome. Two quasi-experimental studies and 5 observational studies had low risk of bias. Low-risk-of-bias studies had outcome estimates similar in magnitude and direction to estimates from high-risk-of-bias studies. Limitation: Most studies failed to adjust for critical confounders and had inadequate definition or assessment of exposures and outcomes. Conclusion: Low-strength evidence suggests an association between achieving NP predischarge thresholds and reduced ADHF mortality and readmission. Primary Funding Source: None.
Lenalidomide and Rituximab in Combination As Initial Treatment of Chronic Lymphocytic Leukemia: Initial Results of a Phase II Study
Authors: Philip A Thompson, Michael J Keating, Christina Hinojosa, Susan C. Smith, Naval G. Daver, Nitin Jain, Jan A. Burger, Zeev Estrov, Susan O'Brien, William G. Wierda, Hagop M. Kantarjian, Alessandra Ferrajoli
Journal: Blood (2014)
Funds are not reaching frontline services
Authors: Liz Walton, Mark Torkington, Kathryn Markus, Ben Jackson, Ben Milton
Journal: BMJ (2016)

We welcome Marshall and Pereira Gray’s editorial on new models for general practice1 and want to report that in our regions the resources promised in the General Practice Forward View 2 have not yet reached frontline services. NHS England pledged a 14% real terms increase in investment in primary care by 2020-21; …
Transdermal skin patch based on reduced graphene oxide: A new approach for photothermal triggered permeation of ondansetron across porcine skin
Authors: Florina Teodorescu, Gurvan Quéniat, Catherine Foulon, Marie Lecoeur, Alexandre Barras, Samia Boulahneche, Mohmaed Salah Medjram, Thomas Hubert, Amar Abderrahmani, Rabah Boukherroub, Sabine Szunerits
Journal: Journal of Controlled Release (2016)
Passport to healthcare: NHS charges become the new normal for overseas patients
Authors: Anne Gulland
Journal: BMJ (2016)

Anne Gulland looks at government plans to improve identification of ineligible patients

Chris Wormald, permanent secretary at the Department of Health, told the public accounts committee earlier this week that the government is considering asking all patients to prove they are entitled to NHS care by showing a passport or some other form of identification.

According to a government commissioned report in 2013 the NHS spends around £2bn (€2.4bn; $2.5bn) a year treating overseas visitors.1 Broken down, these figures show that £1.75bn goes on patients from outside the European Economic Area (EEA); £261m is spent on patients from the EEA, £94m on expats, and £330m on irregular migrants. And despite the headlines about health tourism—that is, people coming to the UK deliberately to get free healthcare—the NHS spends just £60m-£80m on this.

No. Under current rules the NHS can potentially charge for acute and emergency care after admission to hospital, most elective hospital treatments, maternity care, and outpatient appointments. But emergency department care, primary care, treatment for infectious diseases such as tuberculosis or HIV that could pose a threat to the wider public, and some mental health services are all free to overseas patients.

However, it is difficult to know how much the NHS should be trying to claw back. A National Audit Office (NAO) report published in October warned, “Data are incomplete and unreliable, but the …
p14arf/p16ink4a and p15ink4b Gene Expression Profile by Real Time Quantitative PCR at Diagnosis Predicts for Clinical Outcome in Multiple Myeloma Patients.
Authors: Maria E. Sarasquete, Adriana Armellini, Ramon Garcia-Sanz, Ricardo Lopez Perez, Ana Balanzategui, Maria C. Chillon, Patricia Martin-Jimenez, Miguel Alcoceba, Jose M. Hernandez, Marta Fuentes, Rosa M. Lopez, Joan Blade, Maria J. Terol, Alejandro Martin, Javier Fernandez Calvo, Marcos Gonzalez, J.F. J.F. San Miguel
Journal: Blood (2005)
Urine Proteome Specific for Eye Damage Can Predict Kidney Damage in Patients With Type 2 Diabetes: A Case-Control and a 5.3-Year Prospective Cohort Study
Authors: Jin-Kui Yang, Ying-Ying Wang, Chang Liu, Ting-Ting Shi, Jing Lu, Xi Cao, Fang-Yuan Yang, Jian-Ping Feng, Chen Chen, Li-Nong Ji, Aimin Xu
Journal: Diabetes Care (2016)

The predictive value of microalbuminuria (MAU) for kidney damage is limited in type 2 diabetes (T2D). We studied whether a urine proteome specific for sight-threatening proliferative diabetic retinopathy (PDR) is an indicator to predict chronic renal insufficiency (CRI) in patients with T2D.A shotgun urine proteomic analysis was performed in patients with MAU and PDR (case subjects) and in patients with MAU and a duration of T2D for >10 years but without any degree of retinopathy (control subjects). In the cohort study, 210 patients with T2D with an estimated glomerular filtration rate (eGFR) ≥80 mL/min/1.73 m2 were followed for a median of 5.3 years. Urine proteins specific for PDR were used for predicting CRI (eGFR <60 mL/min/1.73 m2).The top two urine proteins with the highest difference in ratio of case subjects to control subjects were haptoglobin (8.7 times; P < 0.0001) and α-2-macroglobulin (5.7 times; P < 0.0001). In the cohort study, patients with baseline urinary haptoglobin ≥20 ng/min (haptoglobinuria) had a higher incidence of CRI than those without (hazard ratio [95% CI] 3.27 [1.41-7.58]; P = 0.006). The overall CRI rate was 3.2% for patients without haptoglobinuria or MAU, 9.5% for those with MAU, and 13.3% for those with haptoglobinuria. The highest rate for CRI (22.4%) was in patients with both MAU and haptoglobinuria (P < 0.001).Urine haptoglobin, which is specific for PDR, is a novel biomarker and complement to urine albumin for predicting kidney damage in patients with T2D.
Germline and somatic multi-gene sequencing in patients (pts) with advanced high grade serous ovarian cancer (HGSOC) and triple negative breast cancer (TNBC)
Authors: N. Stjepanovic, M. Wilson, V. Mandilaras, B. Clarke, H. Berman, R.H. Kim, S. Lheureux, S. Randall Armel, J. McCuaig, A. Volenik, R. Demsky, H. Chow, M. Mysura, L. Siu, P. Bedard, S. Kamel-Reid, T. Stockley, A. Oza
Journal: Annals of Oncology (2016)
Intravital Imaging of Young and Aged Stem Cells in the Marrow of Long Bones: Visualizing Mammalian Stem Cell Behavior in Real-Time in Vivo
Authors: Anja Köhler, Vince Schmithorst, Marie-Dominique Filippi, Marnie A. Ryan, Deidre Daria, Matthias Gunzer, Hartmut Geiger
Journal: Blood (2008)
Predictive Value of Flow Cytometric MRD Analysis in Childhood Acute Lymphoblastic Leukaemia at the End of Remission Induction Therapy.
Authors: J. Motwani, J. Jesson, E. Sturch, L. Eyre, P. Short, M.D. Williams, P.J. Darbyshire, F.G.H. Hill, S. Lawson
Journal: Blood (2007)
Risk of Treatment-Related Stomach Cancer Among Hodgkin Lymphoma Survivors
Authors: Lindsay M. Morton, Ethel S. Gilbert, Charles F. Lynch, Per Hall, Graca M. Dores, Rochelle E. Curtis, Hans H. Storm, Tom Borge Johannesen, Marilyn Stovall, Susan A. Smith, Rita E. Weathers, Berthe M. Aleman, Ruth A. Kleinerman, Joseph F. Fraumeni, Eric J. Holowaty, Eero Pukkala, Magnus Kaijser, Michael Hauptmann, Sophie D. Fossa, Heikki Joensuu, Michael Andersson, Alexandra W. van den Belt-Dusebout, Leila Vaalavirta, Froydis Langmark, Lois B. Travis, Flora E. van Leeuwen
Journal: Blood (2010)
Increased Frequency of HTLV-1 Tax Specific CD8+ Regulatory T-Cells in HTLV-1 Infected Individuals.
Authors: Yohann White, Makoto Yoshimitsu, Tomohiro Kozako, Kakushi Matsushita, Kimiharu Uozumi, Shinsuke Suzuki, Hiroki Kofune, Naomichi Arima
Journal: Blood (2009)
Elimination of the Need for Urine Studies during Diagnostic Studies of Monoclonal Gammopathies by the Combined Use of Serum Immunofixation and Serum Free Light Chain Assays.
Authors: Jerry A. Katzmann, Angela Dispenzieri, Robert Kyle, Melissa R. Snyder, Mathew F. Plevak, Dirk R. Larson, Roshini S. Abraham, John A. Lust, L. Joseph Melton, S. Vincent Rajkumar
Journal: Blood (2006)
Phase I Study of a Liposomal Carrier (CPX-351) Containing a Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in Advanced Leukemias
Authors: Eric J. Feldman, Jeffrey Lancet, Jonathan E. Kolitz, Ellen Ritchie, Alan F. List, Ekatherine Asatiani, Tania J Curcio, Michelle Burton, Marge Fricano, Christine Swenson, Lawrence D Mayer, Arthur C. Louie
Journal: Blood (2008)
Inv (16) Suppresses CEBPA in Acute Myeloid Leukemia by Activation of Calreticulin.
Authors: Daniel Helbling, Beatrice U. Mueller, Nikolai A. Timchenko, David R. Betts, Martine Jotterand, Sandrine Meyer-Monard, Martin F. Fey, Thomas Pabst
Journal: Blood (2004)
OSI-027, a Dual TORC1/TORC2 Inhibitor, Induces Bim- and Puma-Mediated Apoptosis In Lymphoid Malignancy
Authors: Andrea E. Wahner Hendrickson, Mamta Gupta, Seongseok Yun, Jennifer C. Shing, Paula A. Schneider, Kevin L. Peterson, Judith E. Karp, Sharon Barr, Thomas E. Witzig, Scott H. Kaufmann
Journal: Blood (2010)
A Novel STAT3 Inhibitor OPB-31121 Induces Tumor-Specific Growth Inhibition in a Wide Range of Hematopoietic Malignancies without Growth Suppression of Normal Hematopoietic Cells
Authors: Fumihiko Hayakawa, Keiki Sugimoto, Shingo Kurahashi, Takumi Sumida, Tomoki Naoe
Journal: Blood (2011)
Induction of Cell Cycle Arrest and Apoptosis by Dephosphorylation of ERK, Akt, and Bcl-2 and Phosphorylation of JNK by LY293111 in Human Anaplastic Large Cell Lymphoma (ALCL).
Authors: Weiguo Zhang, Marina Konopleva, Teresa McQueen, Wendy Schober, Michael Andreeff
Journal: Blood (2004)
Autologous Stem Cell Transplantation (auto-SCT) as the Treatment of Choice for Follicular Lymphoma Patients in First Relapse: Final Analysis of the Outcome of 175 Patients Treated in the GELA/GOELAMS FL 2000 Study
Authors: Steven Le Gouill, Sophie De Guibert, Christelle Volteau, Marion Fournier, Franck Morschhauser, Chantal Doyen, Pauline Brice, Corinne Haioun, Charles Foussard, Gilles Andre Salles
Journal: Blood (2008)
Genome-Wide Genotype-Based Risk Model for Survival in Acute Myeloid Leukemia Patients with Normal Karyotype.
Authors: Hyeoung-Joon Kim, Hangseok Choi, Yeo-Kyeoung Kim, Sang Kyun Sohn, Joon Ho Moon, TaeHyung Kim, Zhaolei Zhang, Dennis Dong Hwan Kim
Journal: Blood (2012)
Clinical Evaluation of An in Vitro Assay for Rapid Assessment of Cytosine Arabinoside Response in Patients with Acute Leukaemia and Chronic Lymphocytic Leukaemia.
Authors: Elizabeth Anderson, Vyv Salisbury, M. Ann Smith, Mark Ruddock, Ashley Martin, John Lamont, Habib M Alloush, K. Stephen Suh, Graham Smith
Journal: Blood (2009)
NT-ProBNP Is the Strongest Prognostic Factor for Survival in Lymphoma Patients Following Treatment with Curative Intent
Authors: Antonio Salar, Blanca Sanchez-Gonzalez, Alberto Alvarez-Larrán, Josep Comin, Carmen Pedro, Eva Gimeno, Miquel Gómez, Eugenia Abella, Lluis Molina, Franscesc Garcia, Jordi Bruguera, Carlos Besses
Journal: Blood (2008)
Treatment with All-Trans Retinoic Acid and Anthracycline Monochemotherapy in Children with Acute Promyelocytic Leukemia: Analysis of Three Sequential Multicenter Trials of the PETHEMA Group
Authors: Luis Madero, Pau Montesinos, Pilar Bastida, Amparo Verdeguer, Javier De la Serna, Antonio Molines, Purificacion Garcia, Jose Luis Fuster, Maria jose Allegue, Rafael Rojas, Miguel A. Sanz
Journal: Blood (2008)
Randomized Trial of Micafungin Versus Fluconazole in Prophylaxis Against Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients
Authors: Silvia Park, Kihyun Kim, Jun Ho Jang, Seok Jin Kim, Won Seog Kim, Chul Won Jung, Ki Sun Jung, Jinhyun Cho, Kwai Han Yoo, Haa-na Song
Journal: Blood (2015)
Immunohistochemical Expression of CD10, BCL6, and MUM1 in Primary Nodal Diffuse Large B-Cell Lymphoma: MUM1 Expression Alone (but Not Germinal Center B-Cell Immunophenotype) Is an Independent Prognostic Factor.
Authors: Nicholas Wongchaowart, Ena Segota, Tao Jin, Brad Pohlman, Eric D. Hsi
Journal: Blood (2005)
Donor-Recipient Matching For Killer Immunoglobulin-Like Receptor Genotypes Confers Protection Against Graft Versus Host Disease Without Affecting Disease Relapse After Allogeneic Hematopoietic Cell Transplantation
Authors: Rehan M Faridi, Taylor J Kemp, Victor A. Lewis, Noureddine Berka, Jan Storek, Faisal Khan
Journal: Blood (2013)
Total Proteome Analysis Identifies Migration Defects As a Major Pathogenetic Factor in IGHV-Unmutated Chronic Lymphocytic Leukemia
Authors: Gina L Eagle, Rosalind E Jenkins, Kathleen J Till, Jithesh Puthen, Ke Lin, Gillian G Johnson, Melanie Oates, Kevin Park, Neil R Kitteringham, Jianguo Zhuang, Andrew R Pettitt
Journal: Blood (2014)
Identification of Surrogate Prognostic Markers and Genes Implicated in Immunoglobulin Gene (IgVH) Somatic Hypermutation in Small B-Cell Lymphomas.
Authors: Lorraine Tracey, Mohit Aggarwal, Patrocinio Algara, Juan F. Garcia, Monica Garcia-Cosio, Antonia Rodriguez, Nerea Martinez, Francisca I. Camacho, Giovanna Roncador, Abel Sanchez-Aguilera, Elena Ruiz-Ballesteros, Manuela Mollejo, Jose A. Garcia-Marco, Miguel A. Piris
Journal: Blood (2005)
Diabetes Device Use in Adults With Type 1 Diabetes: Barriers to Uptake and Potential Intervention Targets
Authors: Molly L. Tanenbaum, Sarah J. Hanes, Kellee M. Miller, Diana Naranjo, Rachel Bensen, Korey K. Hood
Journal: Diabetes Care (2016)

Diabetes devices (insulin pumps, continuous glucose monitors [CGMs]) are associated with benefits for glycemic control, yet uptake of these devices continues to be low. Some barriers to device uptake may be modifiable through psychosocial intervention, but little is known about which barriers and which patients to target.We surveyed 1,503 adult T1D Exchange participants (mean age 35.3 [SD 14.8] years, mean diagnosis duration 20.4 [SD 12.5] years) to investigate barriers to device uptake, understand profiles of device users versus nonusers, and explore differences by age and sex. Scales used were the Diabetes Distress Scale, Technology Use Attitudes (General and Diabetes-Specific), and Barriers to Device Use and Reasons for Discontinuing Devices.Most commonly endorsed modifiable barriers were related to the hassle of wearing devices (47%) and disliking devices on one's body (35%). CGM users (37%) were older than nonusers (mean 38.3 vs. 33.5 years), had diabetes for longer (22.9 vs. 18.8 years), had more positive technology attitudes (22.6-26.0 vs. 21.4-24.8), and reported fewer barriers to using diabetes technology than nonusers (3.3 vs. 4.3). The youngest age-group (18-25 years) had the lowest CGM (26% vs. 40-48%) and insulin pump (64% vs. 69-77%) uptake, highest diabetes distress (2.2 vs. 1.8-2.1), and highest HbA1c levels (8.3% [67 mmol/mol] vs. 7.2-7.4% [55-57 mmol/mol]).Efforts to increase device use need to target physical barriers to wearing devices. Because young adults had the lowest device uptake rates, highest distress, and highest HbA1c compared with older age-groups, they should be the focus of future interventions to increase device use.
TLR7/8 Agonists Overcome the Suppression of FcγR Activity in Monocytes From Chronic Lymphocytic Leukemia Patients
Authors: Jonathan P. Butchar, Prexy Shah, Hemal Patel, Kavin Fatehchand, Sarwish Rafiq, Carolyn Cheney, John P Vasilakos, Natarajan Muthusamy, John C. Byrd, Susheela Tridandapani
Journal: Blood (2012)
Minimal Residual Disease (MRD) Evaluation by Flow Cytometry in Acute Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation.
Authors: Maria-Belen Vidriales, Jose J. Pérez, Consuelo López-Berges, Norma C. Gutierrez, Juana Ciudad, Lourdes Vazquez, Consuelo del Cañizo, Joaquín Díaz-Mediavilla, Javier Fernández-Calvo, Fernando Ramos, María Jesús Rodriguez, María José Calmuntia, Alberto Orfao, Jesús San Miguel
Journal: Blood (2004)
Microrna 29b Mediates Immune Evasion of Natural Killer Cells in Acute Myeloid Leukemia
Authors: Steven Scoville, Bethany Mundy-Bosse, Michael Zhang, Li Chen, Ryan Sanderson, Tiffany Hughes, Ramiro Garzon, Anjali Mishra, Stefan Costinean, Carlo M. Croce, Aharon G. Freud, Michael A. Caligiuri
Journal: Blood (2015)
Greater Total Dose and Duration of Treatment with Bortezomib Are Associated with Higher Incidence of Chalazion and Other Ocular Side Effects
Authors: Karuna Ganesh, Connie Batlevi, Zhigang Zhang, Hani Hassoun, Nikoletta Lendvai, Heather Landau, Craig H. Moskowitz, Philip Caron, Robert Motzer, Sergio A Giralt, Paul Hamlin, Stuart M. Lichtman, Matthew J. Matasar, Carol S Portlock, Neerav Shukla, Carol Wasserheit-Lieblich, Andrew D. Zelenetz, John F. Gerecitano
Journal: Blood (2014)
Comparison of Contrast-Enhanced CT, PET/CT, PET, and Low-Dose Non-Contrast Enhanced CT Imaging of Diffuse Large B-Cell, Follicular, Small Lymphocytic/CLL, and Marginal Zone Lymphomas.
Authors: Elise A. Chong, Drew A. Torigian, Abass Alavi, Jakub Svoboda, Anthony R Mato, Sunita Dwvedy Nasta, Lisa H. Downs, Stephen J. Schuster
Journal: Blood (2009)
Translocation t(Y;14)(q12;q11): A New Abnormality Associated with r[i(8)(q10)] in T-Prolymphocytic Leukemia Studied by Classic Cytogenetics and Spectral Karyotype.
Authors: Fábio Morato de Oliveira, André F. Marinato, Rafael H. Jácomo, Edgar G. Rizzatti, Roberto P. Falcão, Eduardo M. Rego, Luiz G. Tone, Belinda P. Simões
Journal: Blood (2005)
The Cyclin Dependent Kinase Inhibitor SCH 727965 Demonstrates Promising Pre-Clinical and Early Clinical Activity in Chronic Lymphocytic Leukemia.
Authors: Joseph M. Flynn, Amy J. Johnson, Leslie Andritsos, Kristie A. Blum, Jeffrey A. Jones, Elizabeth A. Wiley, Weihong Hu, Joshua Hessler, Lisa L. Smith, David M. Lucas, Karen Small, Paul Statkevich, Michael R. Grever, Rajat Bannerji, John C. Byrd
Journal: Blood (2009)
Acute Erythroid Leukemia: A Distinctive Subtype of AML? Outcome and Prognostic Factors in Comparison with Non-M6 AML. The Gimema Experience.
Authors: Alessandro Pulsoni, Massimo Breccia, Sonia Maria Orlando, Massimo Bernardi, Marco Borgia, Andrea Camera, Nicola Cantore, Francesco Di Raimondo, Paola Fazi, Felicetto Ferrara, Alberto Bosi, Federico De Angelis, Marco Mancini, Filippo Marmont, Lorella Melillo, Giovanna Meloni, Salvatore Mirto, Giorgina Specchia, Adriano Venditti, Sergio Amadori, Giuseppe Leone, Robin Foa, Livio Pagano
Journal: Blood (2009)
Internal Tandem Duplication Mutation of FLT3 (FLT3/ITD) Significantly Increases Inter Chromosomal Homologous Recombination Providing a Direct Link Between Constitutive FLT3-ITD Activity and Propagation of Copy Neutral Loss of Heterozygosity (CN-LOH) in Acute Myeloid Leukaemia
Authors: Terry J Gaymes, Azim M Mohamedali, Ghulam J. Mufti
Journal: Blood (2014)
Prognostic Implication of Insertion of FLT3 Internal Tandem Duplication in the BETA-1-Sheet of the Tyrosine Kinase Domain-1
Authors: Sabine Kayser, Richard F. Schlenk, Frank Breitenbücher, Martina Porebski, Kerstin Wittke, Juan Du, Silja Groner, Daniela Spaeth, Jürgen Krauter, Arnold Ganser, Hartmut Döhner, Thomas Fischer, Konstanze Döhner
Journal: Blood (2008)
Risk for Post Thrombotic Syndrome (PTS) Development in Children with Extremity Deep Venous Thrombosis (DVT): Results of the US Centers for Disease Control and Prevention (CDC) Pediatric Thrombosis and Hemostasis Centers.
Authors: Marilyn J. Manco-Johnson, Michele G. Beckman, Neil A. Goldenberg, Courtney Thornburg, Lisa A. Michaels, Steven W. Pipe, Stephan Moll, Vilmarie Rodriquez, Roshni Kulkarni
Journal: Blood (2009)
Early Molecular and Cytogenetic Responses Predicts for Significantly Longer Event Free Survival (EFS) and Overall Survival (OS) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) – an Analysis of 4 Tyrosine Kinase Inhibitor (TKI) Modalities (standard dose imatinib, high dose imatinib, dasatinib and nilotinib)
Authors: Preetesh Jain, Hagop M. Kantarjian, Aziz Nazha, Elias Jabbour, Alfonso Quintás-Cardama, Ohad Benjamini, Sherry A. Pierce, Marylou Cardenas-Turanzas, Srdan Verstovsek, Gautam Borthakur, Farhad Ravandi, Susan O'Brien, Jorge E. Cortes
Journal: Blood (2012)
Doctors face manslaughter charge for failing to raise alarm over killer nurse
Authors: Ned Stafford
Journal: BMJ (2016)

Two senior doctors and four nurses in Germany are facing criminal charges of negligent manslaughter for not having taken action to remove a nurse from the intensive care unit in which they strongly suspected him to be murdering patients with overdoses of heart drugs.

Prosecutors said that the six people failed to carry out their duty to protect patients under their care. Because of their inaction, which occurred in 2005, the nurse was able to kill three more patients and to attempt to kill two others before he left the hospital. Conviction of negligent manslaughter carries a sentence of five to 15 years in prison.

The new charges concern the case of a nurse, identified publicly in Germany only as Niels H, because …
Association of Mu Opioid Receptor with Neurogenic Inflammation in Sickle Mic
Authors: Kathryn Luk, Julia Nguyen, Derek Vang, Oludare B Taiwo, Divyanshoo Kohli, Marna Ericson, Michael A Ansonoff, John E Pintar, Robert P Hebbel, Kalpna Gupta
Journal: Blood (2011)
Efficacy and Safety of the Combination of Genasense™ (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia.
Authors: Blanche Mavromatis, Kanti R. Rai, Paul K. Wallace, Claudia Soho, Beverly Landrigan, Patricia Meyn, Tracey Wei, Kenneth K. Chan, Philomena Casey, Steven C. Novick, Asher A. Chanan-Khan
Journal: Blood (2005)
Mechanism of Immune System Activation by (1,4)-α-D-glucan Isolated from Tinospora cordifolia in Macrophages.
Authors: P.K. Raveendran Nair, Steven J. Melnick, Ziad A. Khatib, Reshma Ramachandran, Enrique A. Escalon, Cheppail Ramachandran
Journal: Blood (2006)
Adverse Prognostic Impact of FLT3 Internal Tandem Duplication (ITD) Is Age-Associated in Older [≥60 Years (Y)] De Novo cytogenetically Normal Acute Myeloid Leukemia (CN-AML) Patients (Pts): a Cancer and Leukemia Group B (CALGB) Study.
Authors: Susan P. Whitman, Kati Maharry, Michael D. Radmacher, Krzysztof Mrózek, Dean Margeson, Kelsi B. Holland, Heiko Becker, Yue-Zong Wu, Sebastian Schwind, Maria R Baer, Bayard L. Powell, Richard M Stone, Andrew J. Carroll, Richard A. Larson, Michael A. Caligiuri, Guido Marcucci, Clara D. Bloomfield
Journal: Blood (2009)